1. Home
  2. NRP vs SNDX Comparison

NRP vs SNDX Comparison

Compare NRP & SNDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NRP
  • SNDX
  • Stock Information
  • Founded
  • NRP 2002
  • SNDX 2005
  • Country
  • NRP United States
  • SNDX United States
  • Employees
  • NRP N/A
  • SNDX N/A
  • Industry
  • NRP Coal Mining
  • SNDX Biotechnology: Pharmaceutical Preparations
  • Sector
  • NRP Energy
  • SNDX Health Care
  • Exchange
  • NRP Nasdaq
  • SNDX Nasdaq
  • Market Cap
  • NRP 1.3B
  • SNDX 1.1B
  • IPO Year
  • NRP N/A
  • SNDX 2016
  • Fundamental
  • Price
  • NRP $95.21
  • SNDX $8.95
  • Analyst Decision
  • NRP
  • SNDX Strong Buy
  • Analyst Count
  • NRP 0
  • SNDX 10
  • Target Price
  • NRP N/A
  • SNDX $35.80
  • AVG Volume (30 Days)
  • NRP 26.1K
  • SNDX 1.8M
  • Earning Date
  • NRP 08-06-2025
  • SNDX 07-31-2025
  • Dividend Yield
  • NRP 3.15%
  • SNDX N/A
  • EPS Growth
  • NRP N/A
  • SNDX N/A
  • EPS
  • NRP 10.41
  • SNDX N/A
  • Revenue
  • NRP $229,909,000.00
  • SNDX $43,722,000.00
  • Revenue This Year
  • NRP N/A
  • SNDX $426.77
  • Revenue Next Year
  • NRP N/A
  • SNDX $98.31
  • P/E Ratio
  • NRP $9.17
  • SNDX N/A
  • Revenue Growth
  • NRP N/A
  • SNDX N/A
  • 52 Week Low
  • NRP $81.74
  • SNDX $8.58
  • 52 Week High
  • NRP $113.04
  • SNDX $25.07
  • Technical
  • Relative Strength Index (RSI)
  • NRP 47.90
  • SNDX 38.87
  • Support Level
  • NRP $92.10
  • SNDX $8.92
  • Resistance Level
  • NRP $99.50
  • SNDX $9.56
  • Average True Range (ATR)
  • NRP 2.92
  • SNDX 0.50
  • MACD
  • NRP 0.08
  • SNDX -0.06
  • Stochastic Oscillator
  • NRP 42.03
  • SNDX 15.34

About NRP Natural Resource Partners LP Limited Partnership

Natural Resources Partners LP is a diversified natural resource company. It is engaged in the business of owning, managing and leasing a diversified portfolio of mineral properties in the United States, including interests in coal, trona and soda ash, crude oil and natural gas, construction aggregates, frac sand, and other natural resources. The company leases coal reserves to experience mine operators under long-term leases that grant the operator the right to mine its coal reserves in exchange for royalty payments. The company operates in two reportable segments namely: Mineral Rights and Soda Ash. the majority of the revenue is generated from the Mineral Rights segment. The business activity of the group functions through the United States.

About SNDX Syndax Pharmaceuticals Inc.

Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.

Share on Social Networks: